Neuroinflammation in Hypertension Study

Summary

Neuroinflammation in Hypertension Study is a clinical trial^[1].

Key Facts

• Neuroinflammation in Hypertension Study is in the country of Australia^[2].
• Neuroinflammation in Hypertension Study's instance of is recorded as clinical trial^[3].
• Neuroinflammation in Hypertension Study's start time is recorded as +2020-07-02T00:00:00Z^[4].
• Neuroinflammation in Hypertension Study's end time is recorded as +2022-08-01T00:00:00Z^[5].
• Neuroinflammation in Hypertension Study's main subject is recorded as hypertension^[6].
• Neuroinflammation in Hypertension Study's number of participants is recorded as {'unit': '1', 'amount': '+60'}^[7].
• Neuroinflammation in Hypertension Study's title is recorded as The Role of Neuroinflammation in Hypertension.Minocycline for Resistant Hypertension: a Randomized Double Blind Placebo-Controlled Trial^[8].
• Neuroinflammation in Hypertension Study's short name is recorded as MINIHT^[9].
• Neuroinflammation in Hypertension Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}^[10].
• Neuroinflammation in Hypertension Study's ClinicalTrials.gov ID is recorded as NCT04478500^[11].
• Neuroinflammation in Hypertension Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Neuroinflammation in Hypertension Study's research intervention is recorded as minocycline^[13].
• Neuroinflammation in Hypertension Study's research intervention is recorded as antibiotic^[14].
• Neuroinflammation in Hypertension Study's clinical trial phase is recorded as phase III clinical trial^[15].
• Neuroinflammation in Hypertension Study's research subject recruitment status is recorded as recruiting^[16].
• Neuroinflammation in Hypertension Study's study type is recorded as interventional study^[17].